What Is the IQSM ETF? Returns, Expense Ratio, Holdings, and Alternative ETFs Explained
The New York Life Candriam U.S. Mid Cap ETF (IQSM) is a passive product that selects U.S. mid-cap stocks using ESG criteria and quantitative metrics. Its ESG quantitative screening structure and how its selection and weighting differ from IWR, VO, and IJH are the key factors in choosing it.
What Is the New York Life Candriam U.S. Mid Cap ETF?
This is a passive ETF that quantitatively selects U.S. mid-cap stocks based on environmental, social, and governance criteria. It maintains exposure close to the broader mid-cap market while adjusting individual stock weights using ESG ratings and quantitative metrics.
It suits investors who want to add an ESG perspective and quantitative screening to their U.S. mid-cap exposure and who can tolerate mid-cap volatility.
It is an ETF managed by New York Life using a passive (index-tracking) approach.
How Does the New York Life Candriam U.S. Mid Cap ETF Invest?
| Item | Details |
|---|---|
| Investment target | U.S. mid-cap stocks |
| Management style | Passive (ESG and quantitative screening) |
| Selection criteria | Environmental, social, and governance + quantitative metrics |
| Dividend frequency | Quarterly dividends |
| Total expense ratio | 0.15% |
The ETF tracks an index that adjusts the weights of U.S. mid-cap stocks by combining environmental, social, and governance ratings with quantitative metrics. While maintaining exposure close to the broader mid-cap market, it reduces companies that fall short of ESG criteria and adds weight to highly rated stocks.
- Selection that combines ESG criteria and quantitative metrics
- Weight adjustments while maintaining mid-cap market exposure
New York Life Candriam U.S. Mid Cap ETF Size and Costs (AUM and Management Fee)
Assets under management (AUM) stand at $373.3M, and the total expense ratio is 0.15% per year.
Compared with a simple market-cap-weighted mid-cap ETF, the main points of comparison are ESG and quantitative screening and the weight adjustments.
New York Life Candriam U.S. Mid Cap ETF Performance and Trends
U.S. mid-cap stocks react sensitively to the economic cycle, interest rates, and market risk appetite. Because the ESG and quantitative screening strategy maintains exposure close to the mid-cap market, it generally follows the market's direction, with differences emerging in proportion to the weight adjustments. Given the nature of mid-cap stocks, volatility tends to be higher than for large caps.
Fund flows into ESG and quantitative mid-cap products vary with market risk appetite and demand for sustainability, and money sometimes shifts into this product category when interest in responsible investing rises. It is also worth watching how performance changes with the economic and style cycles.
New York Life Candriam U.S. Mid Cap ETF Pros and Cons
ESG and quantitative screening and mid-cap exposure are its strengths, while mid-cap volatility, tracking differences, and limited excess returns are the considerations.
💪 Key Strengths
⚠️ Points to Watch
New York Life Candriam U.S. Mid Cap ETF Alternative ETFs and Related Products
For mid-cap exposure without ESG and quantitative screening, direct substitutes include IWR and VO, and IJH is another product worth comparing for different mid-cap exposure. What sets this ETF apart is that it combines ESG criteria and quantitative metrics to select U.S. mid-cap stocks, giving it a stronger stock-selection element than a market-cap-weighted index.
| Ticker | Name | Price | Change | AUM | Total Expense Ratio | Dividend Yield | 1Y |
|---|---|---|---|---|---|---|---|
| Schwab Fundamental U.S. Large Company ETF | $32.71 | +0.1% | $28.3B | 0.25% | 1.44% | +23.3% | |
| Invesco RAFI US 1000 ETF | $56.32 | +0.1% | $10.1B | 0.34% | 1.32% | +23.6% | |
| Schwab Fundamental U.S. Small Company ETF | $35.74 | +0.2% | $8.8B | 0.25% | 1.24% | +14.9% | |
| Columbia Research Enhanced Core ETF | $45.81 | +0.5% | $6.2B | 0.15% | 0.71% | +13.3% | |
| John Hancock Multifactor Mid Cap ETF | $73.39 | +0.5% | $6.0B | 0.41% | 0.9% | +12.9% |
| Ticker | Name | Weight | Price | Change | Market Cap | P/E | Dividend Yield |
|---|---|---|---|---|---|---|---|
| RVMD | Revolution Medicines Inc | 0.02% | $194.28 | -1.1% | $41.6B | - | - |
| FTI | TechnipFMC plc | 0.01% | $70.00 | +1.6% | $27.5B | 24.4 | 0.29% |
| Fabrinet | 0.01% | $356.06 | +0.2% | $12.8B | 27.3 | - | |
| XPO Inc | 0.01% | $188.46 | +0.9% | $22.1B | 55.4 | - | |
| Mastec Inc | 0.01% | $180.96 | -3.4% | $14.5B | 28.8 | - | |
| United Therapeutics Corp | 0.01% | $563.49 | +1.7% | $24.2B | 20.2 | - | |
| TWLO | Twilio Inc | 0.01% | $266.68 | +3.1% | $41.0B | 37.1 | - |
| NVT | nVent Electric plc | 0.01% | $146.13 | +4.5% | $23.7B | 40.4 | 0.53% |
| Albemarle Corp | 0.01% | $94.47 | -1.4% | $11.1B | - | 1.71% |
New York Life Candriam U.S. Mid Cap ETF Investor Checkpoints
Here are the points to review before investing in IQSM. ESG and quantitative screening and mid-cap exposure are attractive, but mid-cap volatility, tracking differences, and limited excess returns should be checked in advance. It is also a good idea to compare it with simple mid-cap index products.
| Checkpoint | What to Check | Current Status |
|---|---|---|
| 🌱 ESG and quantitative | Review how ESG ratings and quantitative metrics are combined | Combined screening |
| 🏢 Mid-cap exposure | Review the U.S. mid-cap holdings | Mid-cap exposure |
| ⚡ Volatility | Review mid-cap volatility | On the higher side |
| 💵 Expense ratio | Check the fee of the ESG mid-cap ETF | Needs checking |
Mid-cap volatility and the tracking difference from ESG and quantitative screening are the main variables for long-term performance, and the screening can make the portfolio's composition differ from a market-cap-weighted mid-cap index. Given the nature of mid-cap stocks, drawdowns can be large during market crashes.
It is a suitable candidate for investors who want to add an ESG perspective and quantitative screening to U.S. mid-cap exposure. For mid-cap investing without ESG and quantitative screening, consider products such as IWR and VO, and if you want ESG and quantitative screening, it is advisable to compare this product alongside them before choosing.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. All investment responsibility lies with the investor.
This article reflects information as of June 10, 2026.